¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Other specified abnormal immunological findings in serum"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antirabies serum
    Ç×±¤°ßº´Ç÷û
  • antitetanic serum
    ÇׯĻódzÇ÷û
  • antithymocyte serum
    Ç×°¡½¿»ù¼¼Æ÷Ç÷û, Ç×Èä¼±¼¼Æ÷Ç÷û
  • antitoxic serum
    Ç×µ¶¼ÒÇ÷û
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î³úô¼ö¾×/Ç÷ûºñ
  • allergenic serum
    ¾Ë·¹¸£±âÇ÷û
  • bovine serum albumin
    ¼ÒÇ÷û¾ËºÎ¹Î
  • convalescent serum
    ȸº¹±âÇ÷û
  • fetal bovine serum
    ¼ÒžÆÇ÷û
  • foreign serum
    ÀÌÁ¾Ç÷û
  • hyperimmune serum
    °í¸é¿ªÇ÷û
  • immune human serum globulin
    ¸é¿ª»ç¶÷Ç÷û±Û·ÎºÒ¸°
  • immune serum
    ¸é¿ªÇ÷û
  • icteric serum
    Ȳ´ÞÇ÷û
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunological reaction
    (¢¡immune) ¸é¿ª¹ÝÀÀ
  • immunological recognition
    ¸é¿ªÀÎÁö
  • immunological surveillance
    ¸é¿ª°¨½Ã
  • immunological unresponsiveness
    ¸é¿ª¹«¹ÝÀÀ
  • subtotal abnormal shape
    ºÎºÐÀÌ»óÇüÅÂ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î³úô¼ö¾×Ç÷ûºñ
  • allergenic serum
    ¾Ë·¹¸£°Õ¼ºÇ÷û
  • antilymphocytic serum
    Ç׸²ÇÁ±¸Ç÷û
  • antiplatelet serum
    Ç×Ç÷¼ÒÆÇÇ÷û
  • antirabies serum
    Ç×¹ÌÄ£°³º´Ç÷û
  • antitetanic serum
    ÇׯĻódzÇ÷û
  • antithymocyte serum
    Ç×°¡½¿»ù¼¼Æ÷Ç÷û
  • antitoxic serum
    Ç×µ¶¼ÒÇ÷û
  • bovine serum albumin
    ¼ÒÇ÷û¾ËºÎ¹Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷(~í­Ïàõóúì).
  • abocclusion =abnormal occlusion
    °³±³(ËÒÎá).
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • immunological
    ¸é¿ªÇÐÀû.
  • immunological
    ¸é¿ªÇÐÀû.
  • immunological absorbent
    ¸é¿ªÈíÂøÁ¦.
  • immunological adjuvant
    ¸é¿ªÇÐÀû¾ÆÁÖ¹ÝÆ®
  • immunological adsorbent
    ¸é¿ªÈíÂøÁ¦.
  • immunological competence
    ¸é¿ª´É·Â(¡­Òöæ³).
  • immunological competence
    ¸é¿ª´É·Â(¡­Òöæ³).
  • immunological deficiency state
    ¸é¿ª°áÇÌ »óÅÂ.
  • immunological disease =immunopathy
    ¸é¿ªÁúȯ.
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • immunological homeostasis
    ¸é¿ªÇÐÀûÇ×»ó¼º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abnormal patency of the eustachian tube
    À̰ü°³¹æÁõ
  • abnormal position
    ºñÁ¤»óÀ§Ä¡
  • abnormal reflex
    ÀÌ»ó¹Ý»ç(~ÚãÞÒ).
  • abnormal retinal correspondance
    ÀÌ»ó¸Á¸·´ëÀÀ
  • abnormal shape
    ÀÌ»óÇüÅÂ
  • abnormal temperature
    ÀÌ»ó¿Âµµ, ÀÌ»óü¿Â(~ü¿Â).
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷(~í­Ïàõóúì).
  • abocclusion =abnormal occlusion
    °³±³(ËÒÎá).
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • subtotal abnormal shape
    ºÎºÐÀÌ»óÇüÅÂ
  • total abnormal shape
    ÀüüÀÌ»óÇüÅÂ
  • competence, immunological
    ¸é¿ªÀû°Ý¼º
  • enhancement, immunological
    ¸é¿ªÁõ°­Çö»ó
  • immunological
    ¸é¿ªÇÐÀû.
  • immunological
    ¸é¿ªÇÐÀû.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • precursor of serum prothrombin conversion accelerator
    Ç÷û(úìôè)ÇÁ·ÎÆ®·Òºó Àüȯ°¡¼ÓÁ¦ Àü±¸¹°Áú(ï®üµÊ¥áÜð¥îñÏÌÚªòõ)
  • serum
    Ç÷û(úìôè)
  • serum Ac globulin
    Ç÷û(úìôè) Ac±Û·ÎºÒ¸°
  • serum albumin
    Ç÷û(úìôè) ¾ËºÎ¹Î
  • serum converting enzyme
    Ç÷û Àüȯ È¿¼Ò(úìôèï®üµý£áÈ)
  • serum folate
    Ç÷û(úìôè) Æú»ê(ß«)
  • serum proteins
    Ç÷û ´Ü¹éÁú(úìôèÓ±ÛÜòõ)
  • serum prothrombin conversion accelerator
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÃËÁøÁ¦(ï®üµõµòäð¥)
  • serum prothrombin converting factor
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÀÎÀÚ(ï®üµì×í­)
  • serum sulfation factor
    Ç÷û À¯È²È­ÀÎÀÚ(úìôè×¼üÜûùì×í­)
  • serum thymic factor
    Ç÷û °©»ó¼±ÀÎÀÚ(úìôèË£ßÒàÍì×í­)
  • whole serum
    ÀüÇ÷û(îïúìôè)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ad add [Lat. adde] let there be added [up to a specified amount] [Lat. addetur]; axiodistal; right ear ...
NES not elsewhere specified
NOS network operating system; nitric oxide synthetase; non-organ-specific; not on staff; not otherwise s...
ACF accessory clinical findings; acute care facility; anterior cervical fusion; area correction factor; ...
BREASTS bronchopulmonary aspergillosis, radiotherapy, extrinsic allergic alveolitis, ankylosing spondylitis,...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AIMS Abnormal Involuntary Movement Scale
AIM abnormal involuntary movement
AUB Abnormal Uterine Bleeding
Awd Abnormal wing disc
TAM Transient abnormal myelopoiesis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • abnormal eruption
    ºñÁ¤»ó ¸ÍÃâ
    À¯Ä¡³ª ¿µ±¸Ä¡¿¡ À־ Áö³ªÄ¡°Ô ºü¸£°Å³ª ´Ê°Ô ¸ÍÃâÇÏ´Â Çö»ó.
  • abnormal fetal presentation
    ÀÌ»ó ÅÂÀ§
    žÆÀÇ À§Ä¡°¡ ºñÁ¤»óÀûÀÎ °Í.
  • abnormal frenum
    ÀÌ»ó °è´ë, °è´ë ÀÌ»ó
    Á¤»óÀÌ ¾Æ´Ñ °è´ë, ¼Ò´ë. ¼Ò´ë°¡ Á¤»óº¸´Ù ª°Å³ª ±æ ¼ö ÀÖÀ¸¸ç, ±¸¼ø ¼Ò´ëÀÎ °æ¿ì¿¡´Â 1°³ ÀÌ»óÀÏ ¼öµµ ÀÖ´Ù.
  • abnormal fusion
    ºñÁ¤»ó À¶ÇÕ
    ¹ß»ý ½Ã Á¶Á÷ÀÌ Á¤»óÀûÀ¸·Î ÇÕÃÄÁöÁö ¸øÇÏ´Â »óÅÂ. ´ëºÎºÐ Á¤Áߺο¡ °á¼ÕÀ» ³ªÅ¸³½´Ù.
  • abnormal growth
    ºñÁ¤»ó ¼ºÀå
    ¼ºÀåÀÌ Á¤»óÀûÀÎ ¹üÀ§¸¦ ¹þ¾î³­ »óÅÂ. Á¤»óº¸´Ù »¡¸® ÀÚ¶ö ¼öµµ ÀÖ°í ´Ê°Ô ÀÚ¶ö ¼öµµ ÀÖ´Ù.
  • abnormal jaw closure
    ÀÌ»ó ¾Ç°ñ ±³ÇÕ, ¾Ç°ñ ±³ÇÕ ÀÌ»ó
    ¼Ò±¸Ä¡¿Í ´ë±¸Ä¡ÀÇ ±³ÇÕ¸éÀ̳ª ¹Ý´ëÆí ±³ÇÕ¸éÀÇ Á¢ÃËÀÌ Á¤»óÀ» ¹þ¾î³ª´Â °æ¿ì.
  • abnormal laterality syndrome
    ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıº
    ½ÉÀå¿¡¼­ Á¤»óÀûÀÎ ÁÂ¿ì ´ëĪÀÌ µÚ¹Ù²î°Å³ª ºÒ¿ÏÀüÇÑ °æ¿ì·Î¼­, ÁÂÃøÀ̳ª ¿ìÃøÇüÀ¸·Î ´ëĪÀÎ °æ¿ì°¡ ÀÖ°í À̵鿡¼­ ¿©·¯ °¡Áö ½ÉÀå ±âÇüÀÌ µ¿¹ÝµÇ´Âµ¥ ÀÌ·¯ÇÑ °æ¿ì¸¦ ½ÉÀåÀÇ ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıºÀ̶ó ÇÑ´Ù. À̵é Áúȯ¿¡¼­´Â ½ÉÀå »Ó ¾Æ´Ï¶ó ÁÖ ±â°üÁö¿Í »óÆóµ¿¸ÆÀÇ À§Ä¡ °ü°è ¹× ÆóÀÇ ºÐ¿±, °£°ú ºñÀåÀÇ ÇüÅ ¹× À§Ä¡°¡ ´Þ¶óÁö¸ç ƯÈ÷ ºñÀåÀÌ ¾ø´Â ¹«ºñÁõ
  • abnormal liquid
    ºñÁ¤»ó ¾×ü
  • abnormal movement
    ºñÁ¤»óÀû ¿îµ¿, ÀÌ»ó ¿îµ¿
    »óÇÏ¾Ç Ä¡¿­ ¹× ±³ÇÕÀÌ Á¤»óÀ» ¹þ¾î³ª ¾î±ß³­ »óÅ·ΠÇϾÇÀÌ ¿òÁ÷ÀÌ´Â °Í.
  • abnormal occlusal wear
    ºñÁ¤»ó ±³¸ð, ºñÁ¤»óÀûÀÎ ±³¸ð
    »óÇÏ¾Ç Ä¡¾ÆÀÇ ¸¶Âû·Î ÀÎÇØ ÀϾ´Â Á¤»óÀûÀÎ ±³¸ðº¸´Ù ´õ ¸¹ÀÌ ´â°Å³ª Àû°Ô ´â´Â °æ¿ì·Î¼­ ´ëºÎºÐ Á¤»óº¸´Ù ´õ ¸¹ÀÌ ´â´Â °æ¿ì¸¦ ÀǹÌÇÑ´Ù.
  • abnormal position
    À§Ä¡ ÀÌ»ó
    Á¤»óÀûÀÎ À§Ä¡¿¡¼­ ¹þ¾î³­ »óÅÂ. Á¶Á÷ÀÌ ÀÖ¾î¾ß ÇÒ À§Ä¡¿¡¼­ ¹þ¾î³­ »óÅÂ.
  • abnormal protein
    ºñÁ¤»ó ´Ü¹éÁú
  • abnormal quality
    ºñÁ¤»óÀûÀÎ ¼ºÁú
    Á¤»ó¿¡¼­ ¹þ¾î³­ ¼ºÁú.
  • abnormal regeneration
    ºñÁ¤»ó Àç»ý
    Á¶Á÷ÀÇ Àç»ýÀÌ Á¤»óÀûÀÎ »óÅÂ¿Í ´Ù¸£°Ô ÀϾ´Â °Í.
  • abnormal root
    ÀÌ»ó Ä¡±Ù
    Ä¡±ÙÀÇ Çüųª ¼ö¿¡ ÀÌ»óÀÌ ÀÖ´Â °æ¿ì. À̻󽺷´°Ô ±æ°Å³ª ªÀº ±¼°î±Ù, °úÀ×±Ù, ºÎ±Ù, ½Ö»ý±Ù µîÀÌ ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
immunological Pertaining to immunology.
(18 Nov 1997)
immunological competence <immunology> The bodys ability to develop an immune response to infection or disease. Immunocompetence is measured to see how well the body can fight off certain disease. Many cancer patients become immunocompromised, where their immune system is not as strong as a healthy person's.
(16 Dec 1997)
immunological deficiency Inabillity to mount a normal immune response. Immunodeficiency can be due to a genetic disease or acquired as in aids due to HIV.
(12 Dec 1998)
immunological disease <immunology> Any illness, such as an allergy, that is caused by the action of antibodies.
(09 Oct 1997)
immunological enhancement In immunology, the potentiating effect of specific antibody in establishing and in delaying rejection of a tumour allograft; aside from antibody, non-specific substances may also act to enhance immune response.
Synonym: immunological enhancement.
(05 Mar 2000)
immunological mechanism The groups of cells (chiefly lymphocytes and cells of the reticuloendothelial system) that function in establishing active acquired immunity (induced sensitivity, allergy).
(05 Mar 2000)
immunological memory <immunology> The systems responsible for the situation where reactions to a second or subsequent exposure to an antigen are more extensive than those seen on first exposure (but See immunological tolerance.
The memory is best explained by clonal expansion and persistence of such clones following the first exposure to antigen.
(18 Nov 1997)
immunological network <immunology> The concept due to Jerne that the entire specific immune system within an animal is made up of a series of interacting molecules and cell surface receptors, based on the idea that every antibody combining site carries its own marker antigens or idiotypes and that these in turn may be recognised by another set of antibody combining sites and so on.
(18 Nov 1997)
immunological paralysis Lack of specific antibody production after exposure to large doses of the antigen; immunological paralysis disappears when the antigen is eliminated.
See: immunologic tolerance.
(05 Mar 2000)
immunological surveillance <immunology> The hypothesis that lymphocyte traffic ensures that all or nearly all parts of the vertebrate body are surveyed by visiting lymphocytes in order to detect any altered self material, for example mutant cells.
(18 Nov 1997)
immunological tolerance <immunology> Specific unresponsiveness to antigen. Self tolerance is a process occurring normally early in life due to suppression of self reactive lymphocyte clones.
Tolerance to foreign antigens can be induced in adult life by exposure to antigens under conditions in which specific clones are suppressed. Note that tolerance is not the same as immunological unresponsiveness, since the latter may be very non-specific as in immunodeficiency states.
(18 Nov 1997)
acidified serum test Lysis of the patient's red cells in acidified fresh serum, specific for paroxysmal nocturnal haemoglobinuria.
Synonym: Ham's test.
(05 Mar 2000)
anticomplementary serum Serum that destroys or inactivates complement.
(05 Mar 2000)
antiepithelial serum An antiserum (cytotoxin) for epithelial cells.
(05 Mar 2000)
anti-kidney serum nephritis Experimental glomerulonephritis produced by injection of antiserum to kidney.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á